# US 2026/0184760 A1 · Tethered interleukin-15 and interleukin-21

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0184760 A1
- Document ID: US20260184760A1
- Status: Published application
- Kind: A1
- Application number: 19/561,015
- Filed: 2026-03-09
- Published: 2026-07-02
- Earliest claimed: 2018-02-09
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Inventors: Christian S. Hinrichs; Benjamin Y Jin
- Web page: https://patentgrep.com/patent/US20260184760A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4234: {Interleukins [IL]}
- A61K 40/4272: {Melan-A/MART}
- A61K 40/46: Viral antigens
- C07K 14/5443: {IL-15}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/867: Retroviral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

## Claims

### Claim 1

A nucleic acid molecule encoding a polypeptide comprising a signal sequence, a human interleukin (IL)-15 amino acid sequence, a linker, and a cell membrane anchor moiety,
wherein the linker binds the human IL-15 amino acid sequence to the cell membrane anchor moiety,
wherein the human IL-15 amino acid sequence comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 3; and
wherein the linker sequence is a polypeptide of Formula III: X1mX2nX3pX4q (Formula III), wherein:
each of m, p, and q is, independently, 0 or 1;
n is an integer from 20 to 65;
X2 is independently selected from glycine and serine; and
each of X1, X3, and X4 is, independently, any one naturally occurring amino acid residue.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein the IL-15 amino acid sequence comprises an amino acid sequence at least 95% identical to SEQ ID NO:3.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1, wherein the cell membrane anchor moiety comprises a B7-1 transmembrane-intracellular amino acid sequence, a B7-2 transmembrane-intracellular amino acid sequence, a CD8α transmembrane-intracellular amino acid sequence, a B7-1 transmembrane amino acid sequence, a B7-2 transmembrane amino acid sequence, or a CD8α transmembrane amino acid sequence.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1, wherein the cell membrane anchor moiety comprises an amino acid sequence at least 90% identical to SEQ ID NO:5.

### Claim 5 (depends on 1)

A recombinant expression vector comprising the nucleic acid of claim 1.

### Claim 6 (depends on 5)

The recombinant expression vector of claim 5, wherein the vector is a viral vector.

### Claim 7 (depends on 6)

The recombinant expression vector of claim 6, wherein the viral vector is a lentiviral vector, a retroviral vector, an alphaviral vector, a vaccinial viral vector, an adenoviral vector, an adenoassociated viral vector, a herpes viral vector, or a fowl pox viral vector.

### Claim 8 (depends on 1)

A host cell expressing the nucleic acid molecule of claim 1 or a population of cells comprising the host cell.

### Claim 9 (depends on 8)

The host cell, or population of cells, of claim 8, wherein the host cell is a human cell.

### Claim 10 (depends on 8)

The host cell, or population of cells, of claim 8, wherein the host cell is a primary cell.

### Claim 11 (depends on 8)

The host cell, or population of cells, of claim 8, wherein the host cell is a T cell.

### Claim 12 (depends on 11)

The host cell, or population of cells, of claim 11, wherein the host cell is a tumor infiltrating lymphocyte (TIL).

### Claim 13 (depends on 8)

A pharmaceutical composition comprising the host cell, or population of cells, of claim 8 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

A method of treating cancer in a patient by administering the pharmaceutical composition of claim 13 to the patient.

### Claim 15 (depends on 14)

The method of claim 14, wherein the number of host cells to be administered is about 10×106 to about 10×1011 cells per infusion.

### Claim 16 (depends on 14)

The method of claim 14, wherein the number of host cells to be administered is about 10×109 to about 10×1011 cells per infusion.

### Claim 17 (depends on 14)

The method of claim 14, wherein the number of host cells to be administered is about 10×107 to about 10×109 cells per infusion.

### Claim 18 (depends on 14)

The method of claim 14, wherein the cancer is leukemia, sarcoma, lymphoma, hepatocellular carcinoma, glioma, head-neck cancer, acute lymphocytic cancer, acute myeloid leukemia, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, uterine cervical cancer, gastrointestinal carcinoid tumor, hypopharynx cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, oropharynx, ovarian cancer, pancreatic cancer, penis, peritoneum, rectum, omentum, and mesentery cancer, pancreas, pharynx cancer, prostate cancer, rectal cancer, renal cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, vagina, or urinary bladder cancer.

### Claim 19 (depends on 1)

A method of treating cancer in a patient by administering the nucleic acid molecule of claim 1 to the patient.

### Claim 20 (depends on 1)

One or more polypeptides encoded by the nucleic acid of claim 1.
